Tracleer May Delay Onset of Pulmonary Arterial Hypertension (PAH) in Scleroderma Patients
Early treatment with Tracleer (bosentan) may delay the development of pulmonary arterial hypertension (PAH) in people with scleroderma, according to a study that compared patients who had never used this medicine with those taking it for digital ulcers.
The weather is getting cooler (for most of us), but your produce choices are heating up! These superfoods are either hitting their peak in the garden or can easily be found at your local farmers market or grocery store.
Video: Skin Care and Wound Management in Systemic Sclerosis
We are happy to announce that select videos from the 2016 National Conference are now available online. In this session, Alexandria Crowe, R.N., helps patients understand what
is happening to their skin as Systemic Sclerosis progresses. She also
includes evidence-based therapies to consider. This video and more can be found on our YouTube channel. We will continue to post more videos as them become available.
Reata Pharmaceuticals, Inc. Enrolls First Patient in Phase 3 CATALYST Trial of Bardoxolone Methyl in Connective Tissue Disease-Associated with Pulmonary Arterial Hypertension (CTD-PAH)
Reata Pharmaceuticals, Inc. has
enrolled the first patient into its Phase 3 trial (CATALYST) to evaluate
the efficacy and safety of bardoxolone methyl in patients with
connective tissue disease-associated pulmonary arterial hypertension
Disclaimer: The Scleroderma Foundation in no way
endorses any drugs, treatments, clinical trials, or studies reported in the eLetter. Information is
provided to keep the readers informed. Because the manifestations and severity of scleroderma vary among individuals, personalized medical management is essential. Therefore, it is strongly recommended that all drugs and treatments be discussed with the reader’s physician(s) for proper evaluation and treatment.
The Scleroderma Foundation is a qualified national nonprofit operating under 501(c)(3) status. The foundation’s federal tax identification number is 52-1375827. Our primary goal is to raise funds for our three-fold mission of support, education and research. The foundation has 20 active chapters and 160 support groups across the country.